Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82583 | 1.00 | TBXAS1 (0.37) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29475066 | 1.00 | TBXAS1 (0.37) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL83472 | 0.99 | TBXAS1 (0.36) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL83473 | 0.99 | TBXAS1 (0.36) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15119595 | 0.95 | TBXAS1 (0.33) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL80825 | 0.94 | TBXAS1 (0.39) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL80824 | 0.94 | TBXAS1 (0.39) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL82967 | 0.91 | CYP1A1 (0.35) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL82968 | 0.91 | CYP1A1 (0.35) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29475036 | 0.91 | CYP1A1 (0.35) | TBXAS1CYP1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| CN-109729716-B | PI3K inhibitor combination | 拜耳制药股份公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | BAYER CONSUMER CARE AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | disclosed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | disclosed |
| US-10925880-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | BAYER CONSUMER CARE AG (CH) | 2020-07-16 | — | — | US | disclosed |
| EP-2168582-A1 | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168583-A1 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | TBXAS1 2823/4885CYP1A1 4085/4885CYP1A2 3957/4885 |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | AR, PIK3CA, AKT3 | TBXAS1 1766/4885CYP1A1 1868/4885CYP1A2 1885/4885 |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | TBXAS1 473/4885CYP1A1 2686/4885CYP1A2 2904/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | TBXAS1 321/4885CYP1A1 3065/4885CYP1A2 3496/4885 |
| US-10925880-B2 | Combination of PI3K-inhibitors | BCL9L, BCL9, MALT1 | TBXAS1 4343/4885CYP1A1 2522/4885CYP1A2 2567/4885 |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | AR, GSK3B, PIK3CA | TBXAS1 1558/4885CYP1A1 2533/4885CYP1A2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.